FT 004
Alternative Names: FT-004Latest Information Update: 23 Jan 2024
At a glance
- Originator Frontera Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Haemophilia B
Most Recent Events
- 23 Jan 2024 Clinical trials in Haemophilia B in China (Parenteral) (Frontera Therapeutics pipeline, January 2024)
- 12 Jul 2023 Frontera Therapeutics receives clinical trial approval from Center for Drug Evaluation (part of the National Medical Products Administration) for Hemophilia B in China
- 12 Jul 2023 Pharmacodynamics data from a preclinical trial in Haemophilia B released by Frontera Therapeutics